Direct-acting antivirals for HCV-related hepatocellular carcinoma reduces the risk of tumor progress …

direct acting antivirals for hcv related hepatocellular carcinoma reduces the risk of tumor progression

Sumary of Direct-acting antivirals for HCV-related hepatocellular carcinoma reduces the risk of tumor progression:

  • “While it is deemed low or inconclusive whether DAA therapy helps prevent HCC recurrence, little is known about how the antiviral therapy affects progression of the liver disease after cancer treatment.
  • To account for bias inherent in a single-center retrospective study, a multivariate adjusted time-varying Cox regression analysis showed a 72% reduction in tumor progression in the DAA-treated group and an 88% reduction in risk of death from HCC.
  • Our study showed that eliminating the hepatitis C virus with DAA suppresses tumor progression, which we suggest contributes to overall patient survival.
  • ” Hiroko Ikenaga, First Author HCV infection affects 71 million people worldwide and accounts for about 65% of the causes of liver cancer in Japan.

Want to know more click here go to source.

From -

Close

Site Language


Popular Posts

749

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close